RevolKa Raises $1.7M in Series A Extension to Advance AI-Driven Protein Engineering
RevolKa operates laboratories in Sendai, Japan, where it continues to advance its AI-powered protein engineering technology.
Company Name: RevolKa
Location: Tokyo, Japan
Sector: Biotechnology, AI-Driven Protein Engineering
Funding Details: Raised US$0.7 million and completed a US$1.7 million Series A funding, co-led by D3 and DEEPCORE.
Purpose of Investment: The company plans to use the funds to expand its drug discovery and development activities, particularly focusing on rare diseases.
Product and Innovation: Founded in April 2021, RevolKa is pioneering the creation of novel proteins for therapeutic and industrial applications using its proprietary AI-driven technology platform, aiProtein®. The platform is designed to engineer proteins with enhanced properties, opening new avenues in drug discovery and other industrial applications.
Recent Developments: On July 30th, 2024, RevolKa launched a drug discovery program targeting rare diseases. Some of the drug candidates developed under this program have already achieved positive in vitro proof-of-concept, marking significant progress in the company's mission to address unmet medical needs.
About the Company: RevolKa operates laboratories in Sendai, Japan, where it continues to advance its AI-powered protein engineering technology. The company is dedicated to developing innovative solutions that have the potential to revolutionize therapeutics and industrial processes, leveraging AI to push the boundaries of protein engineering.
